每經AI快訊，4月11日， 匯(hui)(hui)宇制(zhi)(zhi)藥公(gong)(gong)告，全資(zi)子公(gong)(gong)司(si)(si)四川匯(hui)(hui)宇海玥(yue)醫藥科技(ji)有限公(gong)(gong)司(si)(si)收到國家(jia)藥品監督管理(li)局核準簽(qian)發的《受(shou)理(li)通知(zhi)書》，注(zhu)(zhu)射用(yong)HY0001a用(yong)于治療晚期實體瘤的臨床(chuang)試驗(yan)申請獲(huo)得受(shou)理(li)。注(zhu)(zhu)射用(yong)HY0001a為(wei)全資(zi)子公(gong)(gong)司(si)(si)匯(hui)(hui)宇海玥(yue)研發的一種抗體偶聯藥物，注(zhu)(zhu)冊分類為(wei)1類創新型(xing)治療用(yong)生(sheng)物制(zhi)(zhi)品。截(jie)至本(ben)公(gong)(gong)告披露(lu)日，國內外尚無同(tong)靶點產品獲(huo)批上市。本(ben)品為(wei)全球首個披露(lu)針(zhen)對該靶點推向臨床(chuang)的藥物。